The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.
- Resource Type
- Article
- Source
- Current Oncology; Oct2023, Vol. 30 Issue 10, p8805-8814, 10p, 3 Diagrams, 1 Chart
- Subject
LUNG cancer PROTEIN-tyrosine kinase inhibitors CRIZOTINIB OSIMERTINIB CANCER patients - Language
- ISSN
- 11980052